MREO — Mereo BioPharma Group plc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1719714 · United Kingdom
Last close
$0.27
Market Cap
$43.84M
52W High
$2.37
52W Low
$0.20
ADV30
760,412
Next earnings
2026-11-09
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 800,000 800,000 -6,121,000 -5,863,000 29,583,000 26,097,000 5,872,000
Jun 2026 0 0 -6,911,000 -7,005,000 34,714,000 30,118,000 6,062,000
Mar 2026 0 — -8,671,000 -6,719,000 40,614,000 36,223,000 6,560,000
Dec 2025 0 0 -7,917,000 -7,351,000 45,917,000 40,992,000 5,001,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-22,088,000
Investing CF
$-300,000
Financing CF
$39,000
CapEx
$-620,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.20
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-520,406,000
Inventory
—
Receivables
$615,000
ST Investments
—
EBIT TTM
$-26,869,000
Pretax Income TTM
$-26,938,000
Interest Exp TTM
$69,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$800,000
EBITDA
$-28,665,000
Free Cash Flow
$-9,223,250
Enterprise Value
$23,587,946
Total Cash
$26,097,000
Total Debt
$577,000
Shares Out
159,700,637
Trailing EPS
$-0.15
Book Value
$0.15
ROE
-76.6%
ROA
-44.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 500,000 -38,257,000 -41,878,000 45,917,000 5,001,000 40,916,000 -30,971,000
Dec 2024 0 -45,715,000 -43,253,000 76,390,000 15,421,000 60,969,000 -32,834,000
Dec 2023 10,000,000 -27,136,000 -29,466,000 66,499,000 15,962,000 50,537,000 -21,132,000
Dec 2022 0 -52,698,000 -42,220,000 77,413,000 26,011,000 51,402,000 -48,821,000

TTM Snapshot

Revenues TTM
$-332,000
NetIncome TTM
$-28,099,000
OpCashFlow TTM
—
Assets (Latest)
$34,714,000
Forward EPS
$-0.02

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $0.50 · spot: $0.29 · call volume: 202 · put volume: 10
Expected Move to 2027-01-15: ±$0.22 (76.12%) — implied range $0.07 – $0.51 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PRNAF ALTERITY THERAPEUTICS LTD $43.70M $0.20 —
HYFT MindWalk Holdings Corp. $42.60M $0.91 —
ATNM Actinium Pharmaceuticals, Inc. $42.45M $1.35 —
ALDX Aldeyra Therapeutics, Inc. $41.88M $0.69 —
SMNR Semnur Pharmaceuticals, Inc. $46.04M $0.20 —

News headlines (Yahoo Finance, 1h cache)

Mereo BioPharma Reports Third Quarter 2026 Financial Results
2026-11-09 13:00 · Yahoo
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
2026-08-11 12:15 · Yahoo
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
2026-08-11 12:00 · Yahoo
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
2026-08-11 12:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading
2026-06-15 15:09 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
2026-06-02 15:08 · Yahoo
Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-12 11:30 · Yahoo
We're Hopeful That Mereo BioPharma Group (NASDAQ:MREO) Will Use Its Cash Wisely
2026-04-07 13:39 · Yahoo
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
2026-04-02 15:09 · Yahoo
European Equities Traded in the US as American Depositary Receipts Little Changed in Tuesday Trading
2026-02-24 16:03 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.